Literature DB >> 533576

The [14C]-aminopyrine breath test. A comparison of different forms of analysis.

D A Henry, G Sharpe, S Chaplain, S Cartwright, G Kitchingman, G D Bell, M J Langman.   

Abstract

1 Following ingestion of [14C]-aminopyrine, breath 14CO2 data were analysed from normal individuals, patients with hepatic disease, epileptics receiving anticonvulsant therapy and volunteers before and after treatment with glutethimide. 2 The 'standard' 2 h [14C]-aminopyrine breath test discriminated successfully between the main groups but failed to detect the change in microsomal enzyme function produced by glutethimide. 3 A 'modified' form of the 2 h breath test calculated from the area under the breath specific activity curve detected the increase in demethylation following glutethimide. 4 The breath elimination constant (Kb) derived from the breath 14CO2 disappearance curve was as sensitive as the 'modified' 2 h breath test and was simpler to compute. 5 Glutethimide 500 mg/day for 14 days resulted in a 42% increase in the metabolic clearance of antipyrine and a 26% increase in demethylation of [14C]-aminopyrine.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 533576      PMCID: PMC1429896          DOI: 10.1111/j.1365-2125.1979.tb01041.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  11 in total

1.  Aminopyrine metabolism in the presence of hyperbilirubinemia due to cholestasis or hepatocellular disease. Combined use of laboratory tests to study disease-induced alterations in drug disposition.

Authors:  G W Hepner; E S Vesell
Journal:  Clin Pharmacol Ther       Date:  1977-05       Impact factor: 6.875

2.  Disposition of aminopyrine, antipyrine, diazepam, and indocyanine green in patients with liver disease or on anticonvulsant drug therapy: diazepam breath test and correlations in drug elimination.

Authors:  G W Hepner; E S Vesell; A Lipton; H A Harvey; G R Wilkinson; S Schenker
Journal:  J Lab Clin Med       Date:  1977-09

3.  Assessment of aminopyrine metabolism in man by breath analysis after oral administration of 14C-aminopyrine. Effects of phenobarbital, disulfiram and portal cirrhosis.

Authors:  G W Hepner; E S Vesell
Journal:  N Engl J Med       Date:  1974-12-26       Impact factor: 91.245

4.  Effect of subacute administration of methaqualone, phenobarbital and glutethimide on plasma levels of bishydroxycoumarin.

Authors:  J Zaroslinski; R Browne; L Possley
Journal:  Arch Int Pharmacodyn Ther       Date:  1972-01

5.  Urinary D-glucaric acid assay by an improved enzymatic procedure.

Authors:  C J Simmons; M Davis; B Dordoni; R Williams
Journal:  Clin Chim Acta       Date:  1974-02-28       Impact factor: 3.786

6.  Quantitative assessment of hepatic function by breath analysis after oral administration of (14C)aminopyrine.

Authors:  G W Hepner; E S Vesell
Journal:  Ann Intern Med       Date:  1975-11       Impact factor: 25.391

7.  The features of hepatic enzyme induction with glutethimide in man.

Authors:  L Jackson; M Homeida; C J Roberts
Journal:  Br J Clin Pharmacol       Date:  1978-12       Impact factor: 4.335

8.  Aminopyrine demethylation measured by breath analysis in cirrhosis.

Authors:  J Bircher; A Küpfer; I Gikalov; R Preisig
Journal:  Clin Pharmacol Ther       Date:  1976-10       Impact factor: 6.875

9.  Assessment of the (14C) aminopyrine breath test in liver disease.

Authors:  J Galizzi; R G Long; B H Billing; S Sherlock
Journal:  Gut       Date:  1978-01       Impact factor: 23.059

10.  Rate of drug metabolism in man measured by 14CO2-breath analysis.

Authors:  R Platzer; R L Galeazzi; G Karlaganis; J Bircher
Journal:  Eur J Clin Pharmacol       Date:  1978-12-01       Impact factor: 2.953

View more
  15 in total

1.  Drug pharmacokinetics and the carbon dioxide breath test.

Authors:  E A Lane; I Parashos
Journal:  J Pharmacokinet Biopharm       Date:  1986-02

2.  Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in rats and patients.

Authors:  P B Watkins; S A Murray; L G Winkelman; D M Heuman; S A Wrighton; P S Guzelian
Journal:  J Clin Invest       Date:  1989-02       Impact factor: 14.808

3.  Proceedings of the British Pharmacological Society, Clinical Pharmacology Section. Ireland, 6-8 July, 1988. Abstracts.

Authors: 
Journal:  Br J Clin Pharmacol       Date:  1988-11       Impact factor: 4.335

4.  Time course of phenobarbital and cimetidine mediated changes in hepatic drug metabolism.

Authors:  M Døssing; H Pilsgaard; B Rasmussen; H E Poulsen
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

5.  Identification of an inducible form of cytochrome P-450 in human liver.

Authors:  P B Watkins; S A Wrighton; P Maurel; E G Schuetz; G Mendez-Picon; G A Parker; P S Guzelian
Journal:  Proc Natl Acad Sci U S A       Date:  1985-09       Impact factor: 11.205

6.  Assessment of drug metabolism in hepatic disease: comparison of plasma kinetics of oral cyclobarbital and the intravenous aminopyrine breath test.

Authors:  U Breyer-Pfaff; H Seyfert; M Weber; E H Egberts
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

Review 7.  Noninvasive assessment of microsomal enzyme activity in occupational medicine: present state of knowledge and future perspectives.

Authors:  M Døssing
Journal:  Int Arch Occup Environ Health       Date:  1984       Impact factor: 3.015

8.  Omeprazole: effects on oxidative drug metabolism.

Authors:  D A Henry; K W Somerville; G Kitchingman; M J Langman
Journal:  Br J Clin Pharmacol       Date:  1984-08       Impact factor: 4.335

9.  Interpretation of CO2 exhalation rate data from demethylation of aminopyrine and its metabolite monomethylaminoantipyrine.

Authors:  J C Rhodes; L J Aarons; J B Houston
Journal:  Br J Clin Pharmacol       Date:  1982-09       Impact factor: 4.335

10.  Pharmacokinetics of acetohydroxamic acid in patients with staghorn renal calculi.

Authors:  L Putcha; D P Griffith; S Feldman
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.